Filing Flows › Sarepta Therapeutics (SRPT) › Q3 2026 › vs Q2 2026
Sarepta Therapeutics (SRPT) Q3 2026 vs Q2 2026 (quarter over quarter)
Sarepta Therapeutics's revenue fell $19.9M (-5%) from $401M in Q2 2026 to $381M in Q3 2026. The biggest changes: Other revenues −$15.0M (-21%); Elevidys −$14.7M (-15%); Pmo Products +$9.7M (+4%).
Sarepta Therapeutics, Q3 2026: revenue $381M (-4% year over year), operating margin -2.4%, net loss $28.5M, operating cash flow $60.0M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 15.0% | 49.0% | -34.0 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Pmo Products | $240M | $231M | $9.7M | +4% |
| Elevidys | $83.5M | $98.1M | −$14.7M | -15% |
| Other revenues | $57.6M | $72.6M | −$15.0M | -21% |
| Revenue | $381M | $401M | −$19.9M | -5% |
| Net loss | $28.5M | $4.9M | $23.6M | +482% |
| Costs & expenses | $410M | $406M | $3.7M | +0.9% |
| Operating costs | $390M | $388M | $2.4M | +0.6% |
| Interest & other, net | $16.7M | $15.0M | $1.7M | +11% |
| Income tax | $2.7M | $3.1M | −$446K | -14% |
| Research & development | $82.5M | $91.3M | −$8.7M | -10% |
| SG&A | $119M | $108M | $11.0M | +10% |
| Other operating costs | $189M | $189M | $128K | +0.1% |
| Operating cash sources | $88.4M | $202M | −$114M | -56% |
| Depreciation & amortization | $5.9M | $10.4M | −$4.5M | -43% |
| Share-based compensation | $26.7M | $24.5M | $2.3M | +9% |
| Working capital & other | $55.8M | $167M | −$111M | -67% |
| Net loss absorbed | $28.5M | $4.9M | $23.6M | +482% |
| Operating cash flow | $60.0M | $197M | −$137M | -70% |
| Free cash flow (OCF − capex) | $57.0M | $197M | −$139M | -71% |
| Capital expenditures | $2.9M | $555K | $2.4M | +429% |
Questions
How much did Sarepta Therapeutics's revenue grow quarter over quarter in Q3 2026?
Sarepta Therapeutics's revenue fell $19.9M (-5%) from $401M in Q2 2026 to $381M in Q3 2026.
What drove Sarepta Therapeutics's revenue change in Q3 2026?
Other revenues −$15.0M (-21%); Elevidys −$14.7M (-15%); Pmo Products +$9.7M (+4%).